Target intelligence / Profile preview

Glutamate neurotransmitter synthesis pathway

Molecular classification
Other
01

Overview

The **glutamate neurotransmitter synthesis pathway** refers to the biochemical processes by which glutamate, the brain’s primary excitatory neurotransmitter, is synthesized, recycled, and maintained within the central nervous system. Glutamate is predominantly produced in presynaptic neurons from the precursor **glutamine** via the mitochondrial enzyme **glutaminase**[1][2][4]. Glutamine is originally supplied by astrocytes through the action of glutamine synthetase, unique to these glial cells[3][6]. This cooperation forms the **glutamate–glutamine cycle**, essential for recycling neurotransmitter pools and for rapidly terminating glutamate action in the synapse[1][2][3][4]. Within neurons, glutamate is packaged into synaptic vesicles by **vesicular glutamate transporters (VGLUTs)**[1][2]. After release, glutamate is swiftly cleared from the synaptic cleft by sodium-dependent **excitatory amino acid transporters (EAATs)**, present on both neurons and astrocytes. In glial cells, glutamate is converted back to glutamine by **glutamine synthetase**, which is then sent back to neurons for continued neurotransmitter production[1][2][3][6][7]. Disruption of this tightly regulated pathway, especially dysregulation of synaptic glutamate concentration, is linked to several pathologies due to **excitotoxicity**, including ALS, epilepsy, and acute brain injuries[5]. Although components of this pathway (such as glutaminase, glutamine synthetase, and the various transporters) can be considered drug targets, **the pathway itself is not a discrete molecular target but a collection of metabolic and transport steps**, so “Glutamate neurotransmitter synthesis pathway” should not be considered a canonical therapeutic target[1][2][3][4][5][6][7]. **Summary of correctness**: This term refers to a biological pathway rather than a single molecule, receptor, or drug target, so **it is not a canonical therapeutic target** but a description of key biochemical processes involving multiple enzymes and transporters[1][2][3][4][5][6][7].

Other names
Glutamate–glutamine cycleGlutamate biosynthesis pathway
02

Biological functions

Neurotransmitter synthesisSynaptic transmissionSignal terminationAmino acid metabolism
03

Disease associations

Neurodegenerative diseaseEpilepsyNeurotoxicity/ExcitotoxicityOther
04

Safety considerations

Excessive glutamate accumulation can cause excitotoxicity, leading to neuronal injury or death, which is central to diseases like amyotrophic lateral sclerosis (ALS) and potentially implicated in epilepsy and acute brain injury[5].

Beyond the preview

Go deeper on Glutamate neurotransmitter synthesis pathway.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glutamate neurotransmitter synthesis pathway.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call